Simple Summary The availability of Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has
undoubtedly reshaped the initial management of chronic lymphocytic leukemia (CLL) …

Simple Summary Non-covalent Bruton's tyrosine kinase inhibitors (ncBTKi) are being
investigated for the treatment of B-cell malignancies, including chronic lymphocytic leukemia …

Simple Summary Chronic lymphocytic leukemia (CLL) treatment scenario is rapidly
evolving. As a consequence of longer observation, despite remarkable clinical results …

Regulatory T cells (Tregs) are responsible for maintaining immune homeostasis by
controlling immune responses. They can be characterized by concomitant expression of …

In the category of mature B-cell neoplasms, splenic B-cell lymphoma and leukemia were
clearly identified and include four distinct entities: hairy cell leukemia (HCL), splenic …

An innovative strategy for cancer therapy is to combine the inhibition of cancer cell-intrinsic
oncogenic signaling with cancer cell-extrinsic immunological activation of the tumor …

Inhibiting BTK in Chronic Lymphocytic Leukemia | New England Journal of Medicine Skip to
main content The New England Journal of Medicine homepage Advanced Search SEARCH The …

Tirabrutinib is a highly selective Bruton's tyrosine kinase (BTK) inhibitor used to treat
hematological malignancies. We analyzed the anti-tumor mechanism of tirabrutinib using …

Opinion statement The better understanding of the biology of chronic lymphocytic leukemia
(CLL) gained over the past decade has led to the development and introduction of several …

Integrins are adhesion molecules that function as anchors in retaining tumor cells in
supportive tissues and facilitating metastasis. Beta1 integrins are known to contribute to cell …